NCT00635232CompletedPhase 2
A Randomized, Double-Blind, Placebo And Active-Controlled, Parallel Group Study To Evaluate The Dose-Related Efficacy And Safety Of PS433540 In Subjects With Hypertension
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Ligand Pharmaceuticals
- Enrollment
- 261
- Locations
- 40
- Primary Endpoint
- Change From Baseline in Mean Seated Systolic Blood Pressure (SBP) Following 12 Weeks of Treatment With PS433540 200 mg, 400 mg, 800 mg and Placebo.
Study Overview
Brief Summary
The purpose of this study is to learn which doses of PS433540 should be given to patients with high blood pressure to lower their blood pressure. This study will also examine how safe PS433540 is when taken by patients with high blood pressure. Approximately 720 patients will be evaluated so that about 375 patients will be entered into the treatment phase of the study and be given PS433540.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Triple (Participant, Care Provider, Investigator)
Eligibility Criteria
- Ages
- 18 Years to 70 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Males or females 18 - 70 years
- •Mean seated Systolic Blood Pressure (SBP) ≥ 140 mmHg and < 180 mmHg and mean seated Diastolic Blood Pressure (DBP) > 90 and < 109 mmHg at two consecutive qualifying visits (Visits 3/3.5 and Visit 4). The mean difference in DBP between the two consecutive qualifying visits must be ≤ 10 mmHg.
- •Women of child-bearing potential (WOCBP) must use two reliable forms of contraception if sexually active. Alternatively, female subjects must be postmenopausal (for at least 1 year).
Exclusion Criteria
- •Subjects with serious disorders which may limit the ability to evaluate the efficacy or safety of PS433540, including cardiovascular (includes subjects who are known to have coronary artery disease), renal (including the absence of one kidney), pulmonary, hepatic, gastrointestinal (including clinically significant malabsorption), endocrine/metabolic, hematologic, neurologic and psychiatric diseases.
- •History of malignancy other than adequately treated basal cell or squamous cell skin cancer.
- •Subjects with a history of myocardial infarction or New York Heart Association (NYHA) class II-IV heart failure.
- •Subjects with a history of cerebrovascular accident or transient ischemic attack.
- •Subjects with clinically significant cardiac conduction defects, including second or third degree Atrioventricular Block (AV block), left bundle branch block, sick sinus syndrome, atrial fibrillation, atrial flutter, an accessory bypass tract, or any arrhythmia requiring medication.
- •Subjects with hemodynamically significant valvular disease.
- •Subjects with history of type 1 diabetes mellitus and subjects with a history of type 2 diabetes mellitus using antihyperglycemic medication (oral medication, insulin, or exenatide) are excluded.
Arms & Interventions
Irbesartan 300mg
Active Comparator
Irbesartan 300 mg once daily
Intervention: irbesartan (Drug)
Placebo
Placebo Comparator
Blinded Placebo Treatment
Intervention: placebo (Drug)
PS433540 200mg
Experimental
PS433540 200mg once daily
Intervention: PS433540 (Drug)
PS433540 400mg
Experimental
PS433540 400mg once daily
Intervention: PS433540 (Drug)
PS433540 800mg
Experimental
PS433540 800mg once daily
Intervention: PS433540 (Drug)
Outcomes
Primary Outcomes
Change From Baseline in Mean Seated Systolic Blood Pressure (SBP) Following 12 Weeks of Treatment With PS433540 200 mg, 400 mg, 800 mg and Placebo.
Time Frame: 12 weeks
Secondary Outcomes
- Change From Baseline in Mean Seated Diastolic Blood Pressure (DBP) Following 12 Weeks of Treatment With PS433540 200 mg, 400 mg, 800 mg and Placebo.(12 weeks)
- The Percentage of Patients Treated With Each Dose of PS433540 Who Achieved Blood Pressure Control, Defined as <140/90 mmHg, After 12 Weeks of Treatment.(12 weeks)
Investigators
Study Sites (40)
Loading locations...
Similar Trials
Completed
Phase 2
A Trial to Evaluate the Safety and Efficacy of PS433540 to Treat HypertensionHypertensionNCT00522925Ligand Pharmaceuticals280
Completed
Phase 2
Safety Study of Anti-IgE Immunotherapy in Allergic PatientsAllergyNCT00439621Resistentia Pharmaceuticals AB42
Terminated
Phase 2
Maintaining Suppression of Testosterone With Transdermal Estradiol GelCancer of the ProstateNCT02349386BHR Pharma, LLC34
Withdrawn
Phase 2
A Multiple Ascending Dose Study of BMS-707035 in HIV-1 Infected SubjectsHIV InfectionsNCT00397566Bristol-Myers Squibb
Completed
Phase 2
Study to Gather Information About Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following a Recent Non Cardioembolic Ischemic Stroke Which Occurs When a Blood Clot Has Formed Somewhere in the Human Body (But Not in the Heart) Travelled to the Brain.Acute Non-cardioembolic Ischemic StrokeNCT04304508Bayer1,808